Martine Rothblatt Sells 9,500 Shares of United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the business’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $547.91, for a total value of $5,205,145.00. Following the transaction, the chief executive officer owned 40,513 shares of the company’s stock, valued at approximately $22,197,477.83. The trade was a 19.00% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

United Therapeutics Stock Down 0.9%

UTHR traded down $4.66 during trading hours on Tuesday, reaching $539.96. 478,809 shares of the company’s stock traded hands, compared to its average volume of 468,752. The firm has a 50-day moving average price of $566.86 and a 200 day moving average price of $516.87. United Therapeutics Corporation has a 52-week low of $272.12 and a 52-week high of $609.35. The firm has a market capitalization of $22.92 billion, a PE ratio of 19.93, a PEG ratio of 1.81 and a beta of 0.60.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The business had revenue of $781.50 million for the quarter, compared to analysts’ expectations of $797.40 million. During the same quarter in the previous year, the firm earned $6.63 EPS. United Therapeutics’s revenue was down 1.6% compared to the same quarter last year. Equities analysts predict that United Therapeutics Corporation will post 26.92 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages have weighed in on UTHR. TD Cowen reiterated a “buy” rating on shares of United Therapeutics in a report on Thursday, May 21st. Bank of America upped their target price on United Therapeutics from $569.00 to $626.00 and gave the stock a “neutral” rating in a report on Tuesday, March 31st. UBS Group upped their target price on United Therapeutics from $655.00 to $705.00 and gave the stock a “buy” rating in a report on Thursday, March 5th. HC Wainwright upped their target price on United Therapeutics from $600.00 to $660.00 and gave the stock a “buy” rating in a report on Tuesday, March 31st. Finally, Royal Bank Of Canada lowered their target price on United Therapeutics from $707.00 to $701.00 and set an “outperform” rating for the company in a report on Thursday, May 7th. Eleven investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $619.42.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in UTHR. Wellington Management Group LLP increased its position in United Therapeutics by 74.5% during the 4th quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company’s stock valued at $1,189,617,000 after buying an additional 1,042,711 shares in the last quarter. Darwin Global Management Ltd. acquired a new position in shares of United Therapeutics in the third quarter valued at about $317,617,000. Norges Bank acquired a new position in shares of United Therapeutics in the fourth quarter valued at about $293,418,000. Avoro Capital Advisors LLC increased its holdings in shares of United Therapeutics by 17.3% in the fourth quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company’s stock valued at $1,269,803,000 after purchasing an additional 383,838 shares during the period. Finally, Janus Henderson Group PLC grew its holdings in United Therapeutics by 75.1% during the fourth quarter. Janus Henderson Group PLC now owns 796,101 shares of the biotechnology company’s stock worth $387,801,000 after acquiring an additional 341,383 shares during the period. 94.08% of the stock is owned by institutional investors and hedge funds.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.